Standard

Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. / SWITCH Research Group.

In: iScience, Vol. 26, No. 1, 105753, 20.01.2023, p. 105753.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

APA

Vancouver

SWITCH Research Group. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. iScience. 2023 Jan 20;26(1):105753. 105753. doi: 10.1016/j.isci.2022.105753

Author

SWITCH Research Group. / Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. In: iScience. 2023 ; Vol. 26, No. 1. pp. 105753.

BibTeX

@article{14e2d618b1f84d0b848ba4a8203aafec,
title = "Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination",
abstract = "The emergence of novel SARS-CoV-2 variants led to the recommendation of booster vaccinations after Ad26.COV2.S priming. It was previously shown that heterologous booster vaccination induces high antibody levels, but how heterologous boosters affect other functional aspects of the immune response remained unknown. Here, we performed immunological profiling of Ad26.COV2.S-primed individuals before and after homologous or heterologous (mRNA-1273 or BNT162b2) booster. Booster vaccinations increased functional antibodies targeting ancestral SARS-CoV-2 and emerging variants. Especially heterologous booster vaccinations induced high levels of functional antibodies. In contrast, T-cell responses were similar in magnitude following homologous or heterologous booster vaccination and retained cross-reactivity towards variants. Booster vaccination led to a minimal expansion of SARS-CoV-2-specific T-cell clones and no increase in the breadth of the T-cell repertoire. In conclusion, we show that Ad26.COV2.S priming vaccination provided a solid immunological base for heterologous boosting, increasing humoral and cellular responses targeting emerging variants of concern.",
keywords = "Health sciences, immune response, immunology, virology",
author = "Daryl Geers and Sablerolles, {Roos S. G.} and {van Baarle}, Debbie and Kootstra, {Neeltje A.} and Rietdijk, {Wim J. R.} and Schmitz, {Katharina S.} and Lennert Gommers and Susanne Bogers and Nieuwkoop, {Nella J.} and {van Dijk}, {Laura L. A.} and {van Haren}, Eva and Melvin Lafeber and Dalm, {Virgil A. S. H.} and Abraham Goorhuis and Postma, {Douwe F.} and Visser, {Leo G.} and Huckriede, {Anke L. W.} and {SWITCH Research Group} and Alessandro Sette and Alba Grifoni and {de Swart}, {Rik L.} and Koopmans, {Marion P. G.} and {van der Kuy}, {P. Hugo M.} and GeurtsvanKessel, {Corine H.} and {de Vries}, {Rory D.}",
note = "Funding Information: We acknowledge QIAGEN for supporting the study by providing QuantiFERON SARS-CoV-2 RUO Starter and Extended Packs. QIAGEN had no role in study design, data acquisition, and analysis. Assay methodology images were created with Biorender. The NK92.05-CD16 cell line was a kind gift from Kerry S. Campbell at the Fox Chase Cancer Center in Pennsylvania. This work was financially supported by the Netherlands Organization for Health Research and Development ( ZonMw ) grant agreement 10430072110001 to R.D.d.V., C.G.v.K., P.H.M.v.d.K., R.S.G.S, W.J.R.R., V.A.S.H.D., D.v.B., N.A.K., A.G., D.F.P., L.G.V., A.L.W.H., M.P.G.K. D.G., L.G.; R.L.d.S., D.G. and R.D.d.V. are additionally supported by the Health∼Holland grant EMCLHS20017 co-funced by the PPP Allowance made available by the Health∼Holland , Top Sector Life Sciences & Health, to stimulate public –private partnerships. A.G. and A.S. received Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services , under Contract No. 75N93021C00016 to A.S. Funding Information: We acknowledge QIAGEN for supporting the study by providing QuantiFERON SARS-CoV-2 RUO Starter and Extended Packs. QIAGEN had no role in study design, data acquisition, and analysis. Assay methodology images were created with Biorender. The NK92.05-CD16 cell line was a kind gift from Kerry S. Campbell at the Fox Chase Cancer Center in Pennsylvania. This work was financially supported by the Netherlands Organization for Health Research and Development (ZonMw) grant agreement 10430072110001 to R.D.d.V. C.G.v.K. P.H.M.v.d.K. R.S.G.S, W.J.R.R. V.A.S.H.D. D.v.B. N.A.K. A.G. D.F.P. L.G.V. A.L.W.H. M.P.G.K. D.G. L.G.; R.L.d.S. D.G. and R.D.d.V. are additionally supported by the Health∼Holland grant EMCLHS20017 co-funced by the PPP Allowance made available by the Health∼Holland, Top Sector Life Sciences & Health, to stimulate public –private partnerships. A.G. and A.S. received Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. Conceptualization: P.H.M.v.d.K. C.G.v.K. R.D.d.V. Formal analysis: D.G. R.D.d.V. R.S.G.S. Funding acquisition: R.D.d.V. C.G.v.K. P.H.M.v.d.K. R.S.G.S, W.J.R.R. V.A.S.H.D. D.v.B. N.A.K. A.G. D.F.P. L.G.V. A.L.W.H. M.P.G.K. A.S. Investigation: D.G. R.S.G.S, D.v.B. N.A.K. W.J.R.R. K.S.S. S.B. L.G. N.J.N. L.L.A.v.D. M.L. V.A.S.H.D. A.G. D.F.P. L.G.V. A.L.W.H. A.S. A.G. R.L.d.S. M.P.G.K. P.H.M.v.d.K. C.G.v.K. R.D.d.V. Supervision: P.H.M.v.d.K. C.G.v.K. R.D.d.V. Visualization: D.G. R.D.d.V. Writing-original draft: D.G. R.S.G.S. R.D.d.V. Writing: review and editing: all authors reviewed and edited the final version. A.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna, AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. LJI has filed for patent protection for various aspects of T-cell epitope and vaccine design work. The other authors declare no competing interests. Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2023",
month = jan,
day = "20",
doi = "10.1016/j.isci.2022.105753",
language = "English",
volume = "26",
pages = "105753",
journal = "iScience",
issn = "2589-0042",
publisher = "Elsevier Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination

AU - Geers, Daryl

AU - Sablerolles, Roos S. G.

AU - van Baarle, Debbie

AU - Kootstra, Neeltje A.

AU - Rietdijk, Wim J. R.

AU - Schmitz, Katharina S.

AU - Gommers, Lennert

AU - Bogers, Susanne

AU - Nieuwkoop, Nella J.

AU - van Dijk, Laura L. A.

AU - van Haren, Eva

AU - Lafeber, Melvin

AU - Dalm, Virgil A. S. H.

AU - Goorhuis, Abraham

AU - Postma, Douwe F.

AU - Visser, Leo G.

AU - Huckriede, Anke L. W.

AU - SWITCH Research Group

AU - Sette, Alessandro

AU - Grifoni, Alba

AU - de Swart, Rik L.

AU - Koopmans, Marion P. G.

AU - van der Kuy, P. Hugo M.

AU - GeurtsvanKessel, Corine H.

AU - de Vries, Rory D.

N1 - Funding Information: We acknowledge QIAGEN for supporting the study by providing QuantiFERON SARS-CoV-2 RUO Starter and Extended Packs. QIAGEN had no role in study design, data acquisition, and analysis. Assay methodology images were created with Biorender. The NK92.05-CD16 cell line was a kind gift from Kerry S. Campbell at the Fox Chase Cancer Center in Pennsylvania. This work was financially supported by the Netherlands Organization for Health Research and Development ( ZonMw ) grant agreement 10430072110001 to R.D.d.V., C.G.v.K., P.H.M.v.d.K., R.S.G.S, W.J.R.R., V.A.S.H.D., D.v.B., N.A.K., A.G., D.F.P., L.G.V., A.L.W.H., M.P.G.K. D.G., L.G.; R.L.d.S., D.G. and R.D.d.V. are additionally supported by the Health∼Holland grant EMCLHS20017 co-funced by the PPP Allowance made available by the Health∼Holland , Top Sector Life Sciences & Health, to stimulate public –private partnerships. A.G. and A.S. received Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services , under Contract No. 75N93021C00016 to A.S. Funding Information: We acknowledge QIAGEN for supporting the study by providing QuantiFERON SARS-CoV-2 RUO Starter and Extended Packs. QIAGEN had no role in study design, data acquisition, and analysis. Assay methodology images were created with Biorender. The NK92.05-CD16 cell line was a kind gift from Kerry S. Campbell at the Fox Chase Cancer Center in Pennsylvania. This work was financially supported by the Netherlands Organization for Health Research and Development (ZonMw) grant agreement 10430072110001 to R.D.d.V. C.G.v.K. P.H.M.v.d.K. R.S.G.S, W.J.R.R. V.A.S.H.D. D.v.B. N.A.K. A.G. D.F.P. L.G.V. A.L.W.H. M.P.G.K. D.G. L.G.; R.L.d.S. D.G. and R.D.d.V. are additionally supported by the Health∼Holland grant EMCLHS20017 co-funced by the PPP Allowance made available by the Health∼Holland, Top Sector Life Sciences & Health, to stimulate public –private partnerships. A.G. and A.S. received Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. Conceptualization: P.H.M.v.d.K. C.G.v.K. R.D.d.V. Formal analysis: D.G. R.D.d.V. R.S.G.S. Funding acquisition: R.D.d.V. C.G.v.K. P.H.M.v.d.K. R.S.G.S, W.J.R.R. V.A.S.H.D. D.v.B. N.A.K. A.G. D.F.P. L.G.V. A.L.W.H. M.P.G.K. A.S. Investigation: D.G. R.S.G.S, D.v.B. N.A.K. W.J.R.R. K.S.S. S.B. L.G. N.J.N. L.L.A.v.D. M.L. V.A.S.H.D. A.G. D.F.P. L.G.V. A.L.W.H. A.S. A.G. R.L.d.S. M.P.G.K. P.H.M.v.d.K. C.G.v.K. R.D.d.V. Supervision: P.H.M.v.d.K. C.G.v.K. R.D.d.V. Visualization: D.G. R.D.d.V. Writing-original draft: D.G. R.S.G.S. R.D.d.V. Writing: review and editing: all authors reviewed and edited the final version. A.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna, AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. LJI has filed for patent protection for various aspects of T-cell epitope and vaccine design work. The other authors declare no competing interests. Publisher Copyright: © 2022 The Author(s)

PY - 2023/1/20

Y1 - 2023/1/20

N2 - The emergence of novel SARS-CoV-2 variants led to the recommendation of booster vaccinations after Ad26.COV2.S priming. It was previously shown that heterologous booster vaccination induces high antibody levels, but how heterologous boosters affect other functional aspects of the immune response remained unknown. Here, we performed immunological profiling of Ad26.COV2.S-primed individuals before and after homologous or heterologous (mRNA-1273 or BNT162b2) booster. Booster vaccinations increased functional antibodies targeting ancestral SARS-CoV-2 and emerging variants. Especially heterologous booster vaccinations induced high levels of functional antibodies. In contrast, T-cell responses were similar in magnitude following homologous or heterologous booster vaccination and retained cross-reactivity towards variants. Booster vaccination led to a minimal expansion of SARS-CoV-2-specific T-cell clones and no increase in the breadth of the T-cell repertoire. In conclusion, we show that Ad26.COV2.S priming vaccination provided a solid immunological base for heterologous boosting, increasing humoral and cellular responses targeting emerging variants of concern.

AB - The emergence of novel SARS-CoV-2 variants led to the recommendation of booster vaccinations after Ad26.COV2.S priming. It was previously shown that heterologous booster vaccination induces high antibody levels, but how heterologous boosters affect other functional aspects of the immune response remained unknown. Here, we performed immunological profiling of Ad26.COV2.S-primed individuals before and after homologous or heterologous (mRNA-1273 or BNT162b2) booster. Booster vaccinations increased functional antibodies targeting ancestral SARS-CoV-2 and emerging variants. Especially heterologous booster vaccinations induced high levels of functional antibodies. In contrast, T-cell responses were similar in magnitude following homologous or heterologous booster vaccination and retained cross-reactivity towards variants. Booster vaccination led to a minimal expansion of SARS-CoV-2-specific T-cell clones and no increase in the breadth of the T-cell repertoire. In conclusion, we show that Ad26.COV2.S priming vaccination provided a solid immunological base for heterologous boosting, increasing humoral and cellular responses targeting emerging variants of concern.

KW - Health sciences

KW - immune response

KW - immunology

KW - virology

UR - http://www.scopus.com/inward/record.url?scp=85144411101&partnerID=8YFLogxK

U2 - 10.1016/j.isci.2022.105753

DO - 10.1016/j.isci.2022.105753

M3 - Article

C2 - 36507223

VL - 26

SP - 105753

JO - iScience

JF - iScience

SN - 2589-0042

IS - 1

M1 - 105753

ER -

ID: 28875333